Immunization with two experimental vaccines targeting the toxic forms of amyloid-beta and tau protein — two hallmarks of Alzheimer’s disease — triggered an immune response that reduced the levels of both proteins in the brain of a mouse model of the disease. The new combination…
Researchers have discovered a likely reason why the most common form of the CD33 protein is a risk factor for Alzheimer’s disease, a finding that could open new therapeutic avenues targeting the protein, a study reports.
The Bacillus Calmette-Guérin (BCG) vaccine, which provides protection against tuberculosis, can reduce the incidence of Alzheimer’s disease in patients with bladder cancer — and potentially provide new avenues to explore this effect in the general population, according to a recent study. The study, “Bacillus Calmette-Guérin…
The Alzheimer’s Association (AA) has launched an initiative to help U.S. health systems and clinicians enhance dementia care, and do so more cost-effectively. The non-profit organization is seeking to partner with some 300 health systems nationally to offer solutions for improving health outcomes among patients with Alzheimer’s…
Ionis Pharmaceuticals has licensed IONIS-MAPTRx (BIIB080), its investigational antisense therapy for the treatment of Alzheimer’s disease, to Biogen. IONIS-MAPTRx is an antisense therapy — an approach to fighting diseases using short DNA-like molecules called antisense oligonucleotides — that has been designed to reduce the production…
Throughout 2019, Alzheimer’s News Today delivered daily coverage of emerging research, key findings, treatment developments, and clinical trials related to Alzheimer’s disease. We look forward to bringing the same quality of coverage to those living with Alzheimer’s in the coming year. Here are the 10 most-read stories of 2019,…
In awarding more than $100 million to support scientific efforts to prevent, slow or reverse Alzheimer’s disease, the nonprofit Cure Alzheimer’s Fund has reached a significant milestone. Since its founding, the 15-year-old organization has backed some 425 novel projects conducted by 170 investigators worldwide. Those projects have resulted in the…
Troriluzole, an investigational oral therapy by Biohaven, shows a potential to improve cognition and lessen brain volume loss, a sign of Alzheimer’s disease progression, a board reviewing the ongoing Phase 2/3 trial decided. The trial successfully completed its interim futility analysis — meaning it can efficiently reach…
With its annual essay competition, the Alzheimer’s Foundation of America (AFA) is again offering high schoolers affected by Alzheimer’s disease a chance to motivate others and earn money for college. In the AFA Teens for Alzheimer’s Awareness College Scholarship Essay Contest, college-bound high school seniors nationwide are invited…
[Editor’s note: This story, published on Dec. 10, was updated on Dec. 16 with additional details provided by Acadia Pharmaceuticals.] People with Alzheimer’s and other dementias treated with Nuplazid (pimavanserin) in a Phase…
Get regular updates to your inbox.